{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.01","value":"2.53"},{"groupId":"OG001","spread":"1.54","value":"3.40"},{"groupId":"OG002","spread":"0.94","value":"2.72"},{"groupId":"OG003","spread":"0.73","value":"3.04"},{"groupId":"OG004","spread":"2.24","value":"3.24"},{"groupId":"OG005","spread":"1.46","value":"3.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.82","value":"0.02"},{"groupId":"OG001","spread":"1.87","value":"0.03"},{"groupId":"OG002","spread":"1.19","value":"0.97"},{"groupId":"OG003","spread":"1.20","value":"0.59"},{"groupId":"OG004","spread":"1.25","value":"-0.19"},{"groupId":"OG005","spread":"1.29","value":"0.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.14","value":"0.28"},{"groupId":"OG001","spread":"1.94","value":"-0.09"},{"groupId":"OG002","spread":"1.09","value":"0.81"},{"groupId":"OG003","spread":"1.53","value":"1.08"},{"groupId":"OG004","spread":"1.83","value":"0.43"},{"groupId":"OG005","spread":"1.48","value":"0.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.99","value":"0.36"},{"groupId":"OG001","spread":"1.59","value":"-0.33"},{"groupId":"OG002","spread":"1.15","value":"0.16"},{"groupId":"OG003","spread":"0.58","value":"0.02"},{"groupId":"OG004","spread":"2.46","value":"0.09"},{"groupId":"OG005","spread":"0.95","value":"0.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.68","value":"0.18"},{"groupId":"OG001","spread":"1.28","value":"-0.67"},{"groupId":"OG002","spread":"1.08","value":"0.63"},{"groupId":"OG003","spread":"1.05","value":"0.57"},{"groupId":"OG004","spread":"2.49","value":"0.46"},{"groupId":"OG005","spread":"1.25","value":"0.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.71","value":"-0.30"},{"groupId":"OG001","spread":"1.69","value":"-0.54"},{"groupId":"OG002","spread":"1.25","value":"-0.06"},{"groupId":"OG003","spread":"0.53","value":"0.33"},{"groupId":"OG004","spread":"2.92","value":"0.56"},{"groupId":"OG005","spread":"2.00","value":"0.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG000","title":"RRMM Dose-evaluation: Carfilzomib 56 mg/m²"},{"description":"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG001","title":"RRMM Dose-evaluation: Carfilzomib 70 mg/m²"},{"description":"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG002","title":"RRMM Dose-expansion: Carfilzomib 70 mg/m²"},{"description":"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG003","title":"NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²"},{"description":"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG004","title":"NDMM Dose-expansion: Carfilzomib 70 mg/m²"},{"description":"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG005","title":"NDMM Dose-expansion: Carfilzomib 56 mg/m²"}],"paramType":"MEAN","populationDescription":"Participants in the safety analysis set with available data at each time point.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15","title":"Change From Baseline in Neutrophil Count","type":"PRIMARY","unitOfMeasure":"10^9 cells/L"}